Norethindrone Acetate Patch

Description: Norethindrone acetate transdermal delivery system (patch).

Product Details

Duration: One week


Active Pharmaceutical Ingredient (API):

Status Details

Status Details:
  • Phase III completed in 2012. NDA filed with US FDA in 2013. Received complete response letter from FDA in late 2013 (product was not approved).

Additional Information

  • Phase III study conducted by Watson Pharmaceuticals, which is now Actavis. After Actavis bought out Allergan, Actavis began using the Allergan name.

Vertical Tabs